ClinicLens specialt
54 items automatically indexed in this specialt.
← Back to all specialtiesGastroenterology
To explore the safety and efficacy of the novel G protein-biased μ-opioid receptor agonist oliceridine for painless gastroscopy. This study is a single-center randomized controlled clinical trial. One hundred and eighty-eight patients scheduled for painless gastroscopy were rando
Open articleGastroenterology
Liver disease is increasingly prevalent in the general population, with metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) being especially common.1,2 Nevertheless, only about 3% of patients with MASLD have progression to majo
Open articleGastroenterology
Metabolic dysfunction-associated steatotic liver disease (MASLD) commonly coexists with poor muscle health, which encompasses three interconnected domains: muscle mass, muscle function, and muscle quality.1 We refer to this phenotype of impaired muscle health as metabolic syndrom
Open articleGastroenterology
Gender is a crucial determinant in the navigation of a multi-tiered health-care system. Medical misogyny and medical misogynoir, as applied to women of colour, encompass systemic biases, discrimination, and neglect of women's health, and are rooted in historical and patriarc
Open articleGastroenterology
We read the recent analysis of the spectrum of steatotic liver disease in the USA by Zobair Younossi and colleagues1 with great interest. The study addresses an important question about the impact of alcohol under-reporting; however, we believe that the central premise—correction
Open articleGastroenterology
I commend Zobair M Younossi and colleagues1 on their excellent study providing evidence for type 2 diabetes and binge drinking being leading mortality risk factors in steatotic liver disease. When interpreting premature death rates in patients with steatotic liver disease, howeve
Open articleGastroenterology
We thank Kartik Jaidka and colleagues and Hans Scherübl for their thoughtful comments on our recent Article.1
Open articleGastroenterology
Celsa C, Pennisi G, Tulone A, et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroen
Open articleGastroenterology
Quraishi MN, Al-Bawardy B, Banerjee R, et al. Breaking the cycle: from documenting data scarcity to enabling global IBD research. Lancet Gastroenterol Hepatol 2026; 11: 546–49—In this Comment, the corresponding author should have been Mohammed Nabil Quraishi. This correction has
Open articleGastroenterology
24 weeks of treatment with the antisense oligonucleotide bepirovirsen, which targets all hepatitis B virus (HBV) transcripts, resulted in significantly more patients with chronic HBV infection achieving functional cure (defined as an HBV DNA level below the lower limit of quantif
Open articleGastroenterology
HLA-DRB1*01:03 emerges as a genetic determinant of severe disease in both patients with Crohn's disease and patients with ulcerative colitis. Although further validation is needed, assessing HLA-DRB1*01:03 carriage might help identify patients who could benefit from more int
Open articleGastroenterology
The improvement of histological outcomes of eosinophilic gastritis with dupilumab in this proof-of-concept study shows type 2 inflammatory involvement in the disease and the potential value of dupilumab for the treatment of eosinophilic gastritis.
Open articleGastroenterology
Our findings suggest that repeated LSM screening in community-dwelling European populations is feasible. During long-term follow-up, there was a low incidence of clinically significant LSM increase, suggesting that screening should be targeted towards individuals at high risk, su
Open articleGastroenterology
Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ceiling with single agents. This Viewpoint challenges the notion that this ceiling re
Open articleGastroenterology
Post-polypectomy colonoscopy surveillance is widely implemented to reduce colorectal cancer incidence and mortality, yet increasing evidence raises concerns about whether current strategies are optimally balanced in terms of benefit, burden, and resource use. At least some indivi
Open articleGastroenterology
The Colonoscopy Outreach for Rural Communities (CORC) study is a randomized controlled trial testing the effectiveness of a remotely-delivered patient navigation program to increase colonoscopy completion for colorectal cancer (CRC) screening among rural and underserved patients.
Open articleGastroenterology
Objectives: Celiac disease (CD) is an immune-mediated disorder triggered by gluten ingestion. Although a gluten-free diet (GFD) is the only effective treatment, patients may still experience inflammation, nutritional imbalances, and reduced quality of life. Physical activity (PA)
Open articleGastroenterology
Objective: To comprehensively evaluate the efficacy and safety profile of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia in chronic hepatitis B. Methods: A randomized, controlled, multicenter clinical trial was conducted. One hundred p
Open articleGastroenterology
Having both chronic hepatitis B and hepatic steatosis increases the risk of liver-related morbidity and mortality. We aimed to investigate if high-intensity interval training could decrease the liver fat-fraction and improve liver status, body composition, lipid- and glucose meta
Open articleGastroenterology
Bismuth-containing quadruple therapy, the standard Helicobacter pylori (H. pylori) eradication regimen, is limited by adverse events and rising resistance. Vonoprazan-amoxicillin dual therapy offers simplicity but has mostly been tested using high-dose amoxicillin. Data on doxycy
Open articleGastroenterology
Helicobacter pylori infection poses a significant global health burden, with rising antibiotic resistance and treatment-related side effects highlighting the need for adjunctive therapies. Propolis, a natural resin with known antimicrobial and anti-inflammatory properties, suffer
Open articleGastroenterology
Helicobacter pylori infection affects nearly half of the global population and is a major cause of peptic ulcer disease and gastric cancer. Increasing antibiotic resistance, particularly to clarithromycin, has reduced the efficacy of standard triple therapy, necessitating evaluat
Open articleGastroenterology
Inflammatory Bowel Diseases (IBD), including Ulcerative Colitis and Crohn&s Disease, are chronic and recurrent conditions that severely impact patients' quality of life and increase the risk of complications. Providing accurate and evidence-based health information is a
Open articleGastroenterology
Crohn's disease (CD) is a heterogeneous, progressive inflammatory bowel disease in which substantial placebo effects often confound assessment of therapeutic efficacy. A placebo-based disease model was developed using Simple Endoscopic Score for Crohn's Disease (SES-CD)
Open articleGastroenterology
People living with inflammatory bowel disease (IBD) frequently experience abdominal pain, fatigue and faecal incontinence that persist despite optimal medical treatment. This study aimed to assess the cost-effectiveness of IBD-BOOST, a digital, interactive, facilitator-supported
Open articleGastroenterology
Background: The overall objective of this pilot diet intervention study was to determine the effect of grape powder (GP) supplementation on gut microbiota composition and inflammatory markers in individuals with Crohn's disease (CD). Methods: Adult CD participants were recru
Open articleGastroenterology
Evaluation of microscopic inflammation is an emerging therapeutic target of Crohn's disease. The completed VIVID-1 trial evaluated histologic and combined histologic-endoscopic outcomes for mirikizumab relative to placebo and ustekinumab in moderately-to-severely active Croh
Open articleGastroenterology
A randomised controlled trial (RCT) of a facilitator-supported digital programme (IBD-BOOST) for symptom management in Inflammatory Bowel Disease found no difference in disease-specific quality of life and symptom relief compared with controls. Process evaluation is necessary to
Open articleGastroenterology
Evaluation of cleanliness in capsule endoscopy is essential to validate the exam. However, reliable evaluation of bowel cleanliness remains challenging. The validated KODA score provides robust assessment but is time-consuming and impractical in routine practice. We aimed to eval
Open articleGastroenterology
Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD) and impairs quality of life. Hepcidin, the regulator of systemic iron homeostasis, may predict response to iron therapy; however, its utility in IBD remains unclear. This study evaluated whether baseline
Open articleGastroenterology
Xanthohumol (XN), a dietary flavonoid from hops (Humulus lupulus), possesses anti-inflammatory and microbiome-modulatory properties with potential therapeutic benefits for Crohn's disease (CD). To investigate the effects of XN on the gut environment in CD, we conducted a ran
Open articleGastroenterology
Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen in a pressurized chamber and enhances tissue oxygenation and neovascularization. While effective in radiation proctitis, acute severe ulcerative colitis, and perianal fistulizing Crohn's disease, its role in refractory ul
Open articleGastroenterology
A novel tacrolimus lipid suspension (TLS) enema was developed for the management of mild-to-moderate mesalamine-refractory ulcerative colitis (UC). The aim of this study was to evaluate the efficacy and safety of tacrolimus lipid suspension enema 2 mg (TLS-2) and 4 mg (TLS-4) in
Open articleGastroenterology
Background: Ulcerative colitis (UC) is a multifactorial disease characterized by aberrant mucosal immune activation in response to intestinal dysbiosis. Contemporary management strategies aim to target inflammation and microbiome alterations while reducing relapse risk. A multidi
Open articleGastroenterology
Mirikizumab, a p19-directed anti-interleukin-23 antibody, demonstrated efficacy in patients with moderately-to-severely active ulcerative colitis in the global phase 3 LUCENT-1 induction (NCT03518086) and LUCENT-2 maintenance (NCT03524092) trials. The aim was to conduct a pre-spe
Open articleGastroenterology
Augmented mucosal expression of the transcription factor GATA3 has been implicated in the pathogenesis of ulcerative colitis (UC). Here, we evaluated the efficacy and safety of SB012, an enema formulation of the DNAzyme hgd40 that specifically inactivates GATA3 messenger RNA, for
Open articleGastroenterology
LUCENT-URGE (NCT05767021) was a Phase 3b, multicenter, open-label, single-arm study investigating bowel urgency (BU) in patients with moderately-to-severely active ulcerative colitis (UC) and BU at baseline, treated with mirikizumab. Patients without prior mirikizumab exposure re
Open articleGastroenterology
Mirikizumab demonstrated efficacy in moderately-to-severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT-1 [NCT03518086], LUCENT-2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mecha
Open articleGastroenterology
A marked decrease in Faecalibacterium prausnitzii is a hallmark of Crohn's disease (CD)-associated dysbiosis and predicts disease relapse. Here, we present the development and first-in-human evaluation of F. prausnitzii strain EXL01 for CD treatment. The EXL01-strain demonst
Open articleGastroenterology
LIBERTY-CD and LIBERTY-UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti-drug antibodies (ADAs) on clinical outcomes. Patients randomized
Open articleGastroenterology
BACKGROUND: Dye-based chromoendoscopy is recommended for dysplasia surveillance in inflammatory bowel disease (IBD), but virtual chromoendoscopy systems are increasingly used as practical alternatives. Prospective data directly comparing these techniques on a single imaging platf
Open articleGastroenterology
The LIBERTY-CD study demonstrated superior efficacy of subcutaneous infliximab-dyyb over placebo for maintenance therapy in patients with Crohn's disease. This post hoc analysis characterised subgroups of patients with different response levels to subcutaneous infliximab. Gr
Open articleGastroenterology
With increasing antibiotic resistance, treatment of H. pylori infection has gradually become a challenge for clinicians. To compare the efficacy and safety of dual therapy plus bismuth (DTB) with quadruple therapy with bismuth (DBT) for the treatment of H. pylori in patients with
Open articleGastroenterology
Short-term travel, particularly to new environments, can disrupt gut microbiota homeostasis and induce a range of physical and psychological symptoms. While probiotics are proposed to mitigate these effects, evidence from well-controlled trials during domestic travel, especially
Open articleGastroenterology
Respiratory management remains a major challenge during painless endoscopy in overweight or obese patients because of altered body fat distribution and reduced pulmonary reserve. This study evaluated whether ciprofol could reduce respiratory adverse events compared with propofol
Open articleGastroenterology
Objective: To evaluate the effects of a structured language intervention based on predictive coding theory (PCT) on the examination experience and completion status of patients undergoing conventional gastroscopy. Methods: A randomized controlled trial was conducted. The adult pa
Open articleGastroenterology
Objective: We aimed to investigate the effects of a low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet on symptom severity, quality of life, and fecal zonulin levels in patients with irritable bowel syndrome (IBS). Methods: Twenty-four pat
Open articleGastroenterology
Background: Irritable bowel syndrome (IBS)-like symptoms are common in patients with ulcerative colitis (UC) in sustained clinical and endoscopic remission and are associated with impaired quality of life. Evidence for targeted treatments in this setting remains limited. Objectiv
Open articleGastroenterology
Keverprazan offers a new perspective for Helicobacter pylori eradication. This study compared 14-day keverprazan-amoxicillin therapy with esomeprazole-amoxicillin therapy to explore a superior treatment strategy. This was a prospective, open-label, multicenter, randomized control
Open articleGastroenterology
The Review titled “Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review,” published on January 13, 2026, was corrected to update the funding/support section. The middle of the section has “PNRR (MAD-2022-12375656 project)” that should be “European Union (N
Open articleGastroenterology
This first-in-human study evaluated the safety, pharmacokinetics (PK), food effect, and pharmacodynamics (PD) of AJM347, a novel orally active, selective α4β7 integrin antagonist, in healthy Caucasian and Japanese adult males. The study consisted of three parts. In the single-asc
Open articleGastroenterology
There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of po
Open articleGastroenterology
This post hoc analysis evaluated the corticosteroid-sparing effects of risankizumab (RZB) versus ustekinumab (UST) in patients with moderate to severe Crohn's disease (CD) with prior inadequate response or intolerance to ≥ 1 anti-tumor necrosis factor (TNF) therapy. SEQUENCE
Open articleGastroenterology
Study of TOfacitinib for the treatment of chronic PouchITis (STOPit) is a national, investigator-led, multicentre, open-label induction with randomised, double-blind, placebo-controlled maintenance trial to determine the effectiveness of tofacitinib to induce and maintain clinica
Open article